Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?
- 1 October 1999
- journal article
- Published by Elsevier in Life Sciences
- Vol. 65 (18-19), 1973-1976
- https://doi.org/10.1016/s0024-3205(99)00458-0
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Neuroprotective Effect of the Iron Chelator Desferrioxamine Against MPP+ Toxicity on Striatal Dopaminergic TerminalsJournal of Neurochemistry, 1997
- Dopamine, 6-hydroxydopamine, iron, and dioxygen — their mutual interactions and possible implication in the development of Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- The role of transition metals in the pathogenesis of Parkinson's diseaseJournal of the Neurological Sciences, 1995
- Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical studyBrain Research, 1994
- The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controlsNeurochemical Research, 1993
- The possible role of iron in the etiopathology of parkinson's diseaseMovement Disorders, 1993
- Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray MicroanalysisJournal of Neurochemistry, 1992
- Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal gangliaAnnals of Neurology, 1992
- Pathology of Parkinson’s diseaseMolecular and Chemical Neuropathology, 1991
- ParkinsonismNeurology, 1967